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Background:  Monoclonal antibodies (Mabs) that neutralize proprotein convertase subtilisin-kexin type 9 (PCSK9) cause remarkable LDL 
cholesterol (LDL-C) lowering in human trials. It was reported that the efficacy is determined by the epitope of the PCSK9 Mab. Here we 
describe a novel mechanism by which the epitope determines the therapeutic durability of PCSK9 Mabs.
methods:  Mab LY3015014 (LY) was studied in chow-fed cynomolgus monkeys and mice expressing wild-type or a non-cleavable variant 
of human PCSK9 from an adeno-associated viral vector. Serum PCSK9 was determined by immunoassay and mass spectrometry. LDL-C 
was determined by size exclusion chromatography. Furin cleavage of PCSK9 in vitro was evaluated by electrophoresis.
results:  A single 5 mg/kg dose of LY decreased LDL-C in monkeys for more than 30 days. LY did not cause an accumulation of intact 
PCSK9 in serum, which was seen preclinically and in humans treated with other PCSK9 Mabs. Because the LY epitope excludes the furin 
cleavage site in PCSK9, we asked if furin-mediated degradation proceeds when LY is bound but is blocked by other Mabs. Co-incubation 
of PCSK9 and furin with a control IgG4 or LY resulted in the cleavage of PCSK9 to a smaller form, which we reported to be inactive as a 
regulator of LDL-C. In contrast, Mabs whose epitopes overlap the furin site in PCSK9 blocked the in vitro cleavage by furin. Two of these 
share the complementarity determining regions of Mabs whose LDL-lowering efficacy has been confirmed in humans. These Mabs caused 
significant accumulation of serum PCSK9 when administered to mice expressing wild-type human PCSK9, whereas LY did not, and they 
displayed a shorter duration of LDL-lowering. To determine if blocking cleavage accounted for PCSK9 accumulation, we tested the Mabs 
in mice expressing the non-cleavable human PCSK9. In these mice, LY caused PCSK9 accumulation and its duration of LDL lowering was 
reduced, similar to the Mabs that blocked cleavage.
Conclusion:  LY displays a unique property in that it permits the normal proteolytic degradation of PCSK9. The proteolysis prevents 
significant accumulation of Mab-bound PCSK9 and extends the therapeutic durability of LY relative to the other Mabs studied.
